Enzyme Replacement Therapy for CLN2 Disease: MRI Volumetry Shows Significantly Slower Volume Loss Compared with a Natural History Cohort
Authors:
- Pritika GaurPGPritika Gaur
- Paul GissenPGPaul Gissen
- Asthik BiswasABAsthik Biswas
- Kshitij MankadKMKshitij Mankad
- Sniya SudhakarSSSniya Sudhakar
- Felice D’ARcoFDFelice D’ARco
- Angela SchulzASAngela Schulz
- Jens FiehlerJFJens Fiehler
- Jan SedlacikJSJan Sedlacik
- Ulrike LöbelULUlrike Löbel
- 8 July 2024
- journal article
- research article
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 45 (11) , 1791-1797
Abstract
BACKGROUND AND PURPOSE: Neuronal ceroid lipofuscinoses (NCL) are a group of neurodegenerative disorders. Recently, enzyme replacement therapy (ERT) was approved for CLN2, a subtype of NCL. The aim of this study was to quantify brain volume loss in CLN2 disease of patients on ERT in comparison to a natural history cohort using magnetic resonance imaging (MRI). MATERIALS AND METHODS: Nineteen (13 female, 6 male) patients with CLN2 disease at one UK center were studied using serial 3D T1-weighted MRI (follow-up time, 1 to 9 years). Brain segmentation was done using FreeSurfer. Volume measurements for supratentorial grey and white matter, deep grey matter (basal ganglia/thalami), lateral ventricles, and cerebellar grey and white matter were recorded. The volume change over time was analyzed using a linear mixed-effects model excluding scans before treatment start. Comparison was made to a published natural history cohort of 12 patients (8 female, 4 male) which was reanalyzed using the same method. RESULTS: Brain volume loss of all segmented brain regions was much slower in treated patients compared to the natural history cohort. For example, supratentorial grey matter volume in treated patients decreased by 3±0.74% (p<0.001) annually compared to an annual volume loss of 16.8±1.5% (p<0.001) in the natural history cohort. CONCLUSIONS: Our treatment cohort showed a significantly slower rate of brain parenchymal volume loss compared to a natural history cohort in several anatomical regions. Our results complement prior clinical data which found a positive response to ERT. We demonstrate that automated MRI volumetry is a sensitive tool to monitor treatment response in children with CLN2 disease. ABBREVIATIONS: NCL = Neuronal Ceroid Lipofuscinosis, CLN2 = Neuronal Ceroid Lipofuscinosis type 2, TPP1 = tripeptidyl peptidase 1, ERT = enzyme replacement therapy, EMA = European Medicines Agency, ICV = intra-cerebro-ventricular reservoir.Keywords
This publication has 24 references indexed in Scilit:
- Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension studyThe Lancet Neurology, 2023
- Magnetic resonance brain volumetry biomarkers of CLN2 Batten disease identified with miniswine modelScientific Reports, 2023
- Natural history of MRI brain volumes in patients with neuronal ceroid lipofuscinosis 3: a sensitive imaging biomarkerNeuroradiology, 2022
- MRI in CLN2 disease patients: Subtle features that support an early diagnosisEuropean Journal of Paediatric Neurology, 2020
- Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort studyThe Lancet Child & Adolescent Health, 2018
- Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosisMolecular Genetics and Metabolism, 2015
- FreeSurferNeuroImage, 2012
- Intraventricular Enzyme Replacement Improves Disease Phenotypes in a Mouse Model of Late Infantile Neuronal Ceroid LipofuscinosisMolecular Therapy, 2008
- Decreased T2 signal in the thalami may be a sign of lysosomal storage diseaseNeuroradiology, 2007
- MRI in neuronal ceroid lipofuscinosisNeurological Sciences, 2000